-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $119

Benzinga·07/08/2026 16:32:51
Listen to the news
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $126 to $119.